Biomarkers and Personalized Medicine
A biomarker is defined as a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention.
Biomarkers are of increasingly high importance in medicine, particularly in the realm of “personalized medicine.” They are valuable for predicting prognosis and treatment selection. Moreover, they may be helpful in detecting therapeutic responses. Thus, biomarkers are essential tools for the selection of appropriate patients for treatment with certain drugs and to enable personalized medicine, that is, “providing the right treatment to the right patient, at the right dose at the right time.”. Diagnostic biomarkers are important in autoimmune diseases, and disease severity biomarkers are helpful tools in the treatment for inflammatory eye diseases.
The aim of this review is to identify, qualify, and implement the different kind of biomarkers of choroidal diseases.
Anatomy of the Choroid
The choroid is the vascular component that nourishes the outer portion of the retina.
The choroid is composed of various layers:
Bruch's membrane is a thin lamina resulting from the fusion of the basal laminae of the retinal pigment epithelium (RPE) and the choriocapillaris. Bruch's membrane is 2–4 μm thick and extends from the margin of the optic disc to the ora serrata. Ultrastructurally, it is composed of five sublayers: (i) the basement membrane of the RPE, (ii) the inner loose collagenous zone, (iii) a thicker, porous band of elastic fibers, (iv) the outer collagenous zone, and (v) the basal lamina of the endothelium of the choriocapillaris.
The choriocapillaris is a continuous layer of large capillaries of 40–60 μm in diameter, lying in a single plane between Bruch's membrane and the Sattler's layer. The vessel walls are extremely thin and contain multiple fenestrations. These fenestrations are located mostly on the retinal side. Furthermore, the fenestrae of the choriocapillaris (CC) are notable for their large size (approximately 800 Å) and the presence of an overlying diaphragm. The choriocapillaris are organized into a series of hexagonal-shaped lobules [Fig. 1a], which are smaller at the posterior pole (200–350 μm in diameter), and became progressively larger toward the periphery. The lobule is supplied centrally by a precapillary arteriole that drains peripherally into the postcapillary venule. Arterial blood reaches the lobule at its center, circulates centripetally toward the edge of the lobule, and, subsequently, drains into the venous system. The choriocapillaris lobules are separated by many tiny intercapillary spaces that may grow with age (according to a power distribution) and disease (e.g., myopia, hypertension, age-related macular degeneration [AMD]). The main function of the choriocapillaris is to supplement the RPE and the outer retina with oxygen, micronutrients, ions, and water. When choriocapillaris does not provide a sufficient perfusion, RPE and the outer retina suffer a metabolic stress and hypoxemia.
The larger vessels of the choroid have an average diameter of 28.2 and 37.1 μm, for arteries and veins, respectively. These vessels constitute two layers: the outer Haller's layer of large arteries and veins and the inner Sattler's layer of medium vessels that feed and drain the choriocapillaris (Krebs 1988) [Fig. 1b].
Finally, the suprachoroidal space is a zone of transition between choroid and sclera containing elements of both.
The thickness of the choroid is variable depending on location, with a maximum of 0.22 mm at the posterior pole and with a thickness reduced to 0.1 mm at the ora serrata. Perfusion of the choroid comes from both the long and short posterior ciliary arteries and from the perforating anterior ciliary arteries [Fig. 2]. Venous blood drains through the vortex system. The physiological peculiarity of choroidal tissue is represented by its hemodynamic characteristics: this is vascular tissue with the highest blood flow in the whole body, and as a result, the venous blood is just slightly less saturated in oxygen than the arterial oxygen pressure.
Melanocytes, connective tissue, and cells of the immune system are interspersed in between the vessels of the choroidal stroma.
Comparison of Currently Available Imaging Modalities for Choroidal Assessment
The alterations in the choroidal tissue are central to the pathogenesis of conditions, such as age-related choroidal atrophy, myopic chorioretinal atrophy, central serous chorioretinopathy (CSCR), chorioretinal inflammatory diseases, among others. Indocyanine green angiography (ICGA) is traditionally the gold standard for evaluation of the choroidal circulation. Newer imaging modalities, including enhanced-depth imaging optical coherence tomography (EDI-OCT), swept-source optical coherence tomography (SS-OCT), and optical coherence tomography angiography (OCTA) have greatly improved the visualization of the choroidal anatomy. Further, imaging analyses tools such as volumetric analysis, image averaging tools, and various third-party software have enhanced our capabilities of image interpretation and evaluation. The following section summarizes the currently available imaging modalities that aid in the assessment of various choroidal disorders.
Indocyanine green angiography
Indocyanine green (ICG) is a water-soluble and highly protein-bound (98%) dye, which has limited diffusion through the small fenestrations of the choriocapillaris. The retention of ICG in the choroidal circulation, and its low permeability, makes ICGA ideal for imaging choroidal circulation. ICG absorbs and reflects in the near-infrared portion of the spectrum (805 and 835 nm, respectively). It can be detected only with specialized infrared video angiography using modified fundus cameras, a digital imaging system, or a scanning laser ophthalmoscope (SLO). Due to its long operating wavelength, it fluoresces better through the RPE, lipid and hemorrhage facilitating the visualization of the choroid through subretinal hemorrhage or other pigmentary deposits in the retina or RPE. However, it is an invasive procedure with potential adverse reactions and contraindications.
Enhanced-depth imaging optical coherence tomography
On spectral-domain optical coherence tomography (SD-OCT), a broadband light source with a wavelength of 850 nm is split into a reference arm and a sample arm in order to reconstruct the microscopic structure of the chorioretinal tissue. Tomographic images obtained with SD-OCT devices generally exhibit better quality if they are placed near the zero-delay line, which, in the conventional technique, is placed at the level of the posterior vitreous. The outer limit of the choroid and the sclera cannot usually be reliably identified using conventional SD-OCT due to scattering of light from pigmented RPE layer as well as decreasing sensitivity and resolution with increasing displacement from zero-delay line.
EDI-OCT is an acquisition technique in which the peak sensitivity is placed posteriorly, further toward the sclera, so the roll-off of sensitivity does not compromise the registration of deeper structures such as the choroid and choroidal–scleral interface. Therefore, in conditions such as pathological myopia where the choroid and sclera are thin, the complete depth of the sclera and the orbital fat may be visualized. Although EDI-OCT contributes to enhanced overall assessment of the choroid and choroidal–scleral interface, the technique does not contribute significantly to the visualization of the choriocapillaris and choroidal microvasculature due to their proximity to the RPE.
Swept-source optical coherence tomography
In comparison to SD-OCT, SS-OCT uses a different light source (wavelength-tunable laser) and a different detection method (dual balanced photo detector), which confer the advantages of higher imaging speed, higher detection efficiencies, improved imaging range, and reduced sensitivity roll-off with increasing depth. SS-OCT has the highest imaging speed of any commercially available OCT with 100,000 A-scans obtained per second. This improves scan quality by reducing the negative effect of patient's eye movement and allows for denser scan patterns and larger scan areas compared with SD-OCT scans for a given acquisition time. It has a high axial resolution of 5 μm and an improved signal-to-noise ratio which leads to better imaging of the internal structure of the choroid including the choriocapillaris and the choroidoscleral interface. Furthermore, the long wavelength of SS-OCT (1,050 nm) is less subject to light scatter by the RPE and lens opacities resulting in enhanced light penetration through the RPE, as well as better detection of signals from the deeper layers.
Optical coherence tomography angiography
OCTA is a novel imaging technique that provides noninvasive angiographic maps of the retinal and choroidal vasculature without the need for intravascular contrast agent. OCTA is able to detect endoluminal flow and allows detailed depth-resolved analysis of the microvascular network in each layer of the retina and choroid revealing subtle abnormalities that may not be detectable on routine fluorescein angiography (FA) and/or ICGA. While standard angiography provides two-dimensional images, OCTA offers three-dimensional optical reconstruction of the tissue, based on a volumetric dataset. OCTA has proven to be useful in documentation of in vivo choriocapillaris and choroidal vasculature in a reproducible manner and is an invaluable tool in the investigation of the choroid in physiological or pathological conditions such as choriocapillaris ischemia and choroidal neovascular membrane (CNV). Focal absence of choriocapillaris on OCTA or flow deficit areas may represent true choriocapillaris atrophy with complete loss of vessels, reduced blood flow, or simply an image artifact and needs to be carefully interpreted. Choriocapillaris ischemia detected on OCTA correlates very well with the hypocyanescent lesions seen on ICGA. Sometimes the flow deficit areas may be seen due to loss of signal transmission that needs to be ruled out using structural enface scans. Although OCTA is very useful for the evaluation of the choriocapillaris layer of the choroid, the medium and large choroidal vessels are not very well appreciated with this imaging technique.
Choroidal Biomarkers in Age-Related Macular Degeneration
Historically, ICGA was extremely useful in AMD when the treatment for CNVs was laser photocoagulation, and ICGA could help localize an extrafoveal vessel making it accessible to treatment. With the advent of anti-vascular endothelial growth factor (VEGF) treatment, and high-quality noninvasive imaging like SD-OCT, and with an increased volume of patients in busy clinical setting, the use of invasive imaging modalities such as FA and ICGA has drastically decreased.
However, the gold standard for CNV detection is currently still FA. Nevertheless, many studies have reported that ICGA can improve the ability to detect CNV in patients with neovascular AMD compared with FA alone, particularly when type 1 CNV is present. In these studies, ICG angiograms obtained using both SLO and digital video-angiography enabled visualization of 55% and 61% of CNV, respectively, in cases where the CNV could not be determined with FA alone. Detection of classic CNV on ICG angiography reportedly approaches 100% in patients with neovascular AMD, thanks to the longer wavelength of ICGA that allows detailed visualization of deeper retinal structures and choroidal circulation through sero-sanguineous pigment epithelium detachments, which are a common biomarkers of neovascular activity in CNV and often hinder OCT view as they can attenuate the signal.
Rush et al. have shown that ICGA size of CNV measured at baseline and after 2 months of intravitreal treatment holds a prognostic value, irrespective of CNV type. In particular, a decrease in size ≥33% is associated with significant decrease in size or complete disappearance of CNV at 12 months and is significantly more likely to gain over three lines of visual acuity. This CNV size evaluation through ICGA can be used to identify the subset of patients that may not require regular anti-VEGF therapy beyond 12 months 14.
At present, the possibility of accurately assessing the size of the CNV by OCTA is possible but limited by the technology itself: different size of acquisition field as well as different software used to elaborate the size, in addition to the known projection artifact and motion artifact, make it difficult to properly compare studies. It appears that the size of CNV assessed on OCTA is smaller than the ICGA assessment, but significant variability has been described depending on the use of SS-OCT or SD-OCT.
IGCA also holds a place in cases of inflammatory diseases of the elderlies where CNVs occur in the absence of choroiditis and vitreous inflammation. Invernizzi et al. have recently published a case series in which CNV was the presenting feature of intraocular tuberculosis in elderly patients living in nonendemic areas. These cases were initially misdiagnosed as AMD, with poor response to anti-VEGF treatment. ICGA was able to detect choroidal involvement (tubercular granulomas/choroiditis) in the absence of any apparent signs of intraocular inflammation detectable by funduscopic examination or by routine ocular imaging techniques such as OCT and FA.
ICGA is also still the only imaging modality that can help identifying feeder vessels that may be accessible to direct photocoagulation, particularly in patients with high cardiovascular risk and comorbidities or social constraints preventing them from repeated intravitreal injections.
Choroidal Biomarkers in Pachychoroid Disease
Pachychoroid diseases started to be discussed in 2013 when Freund et al. described pachychoroid pigment epitheliopathy (PPE). The pachychoroid disease spectrum includes PPE, CSCR, pachychoroid neovasculopathy (PNV), and aneurysmal type 1 neovascularization (polypoidal choroidal vasculopathy). Focal choroidal excavation and peripapillary pachychoroid syndrome were recently added to this spectrum. Features of the pachychoroid phenotype are choroidal hyperpermeability, dilated choroidal vessels (pachyvessels), and focal or diffuse increase in choroidal thickness, best seen with EDI-OCT or SS-OCT. Pachychoroid vascular changes co-localize with focal disruptions in the RPE and Bruch's membrane, leading eventually to the various clinical manifestations. ICGA shows choroidal hyperpermeability in these regions. En face OCT imaging demonstrates that pachyvessels are often attributable to pathologically dilated veins of Haller's layer that cause a secondary, corresponding attenuation of the overlying inner choroidal layers. Using OCTA, Gal-Or et al. identified and quantified areas of signal voids in the choriocapillaris and demonstrated that inner choroidal flow signal attenuation is topographically associated with pachyvessels.
Choroidal Biomarkers in Central Serous Chorioretinopathy
CSCR is a major cause of central vision loss in young adults, with an incidence of approximately 1/10,000 and a male: female ratio between 72% and 88%. CSCR can occur in an acute form or relapse in a chronic form, defined as such if it persists for at least 6 months. Although acute episodes usually resolve spontaneously within 2–3 months, relapses, and/or chronic evolution occur in 30%–50% of cases, resulting in visual loss secondary to retinal thinning and foveal cysts, without an approved treatment available at the time. It is referred as a “chorioretinopathy” since it appears to involve the retina, with a variable area of detachment of the neuroepithelium, but starting from an alteration of the barrier and channel pump in the choriocapillaris. CSCR primarily occurs because of disturbance in choroidal circulation with hyperpermeability and dilatation of choroidal vessels. This choroidal hyperpermeability can be documented in CSCR with ICGA [Fig. 3a] and is thought to contribute to the development of serous pigment epithelial detachments (PEDs) and accumulation of subretinal fluid. The role of the choroid in the pathogenesis of CSCR has been further confirmed by SD-OCT studies, which have demonstrated an overall increase in choroidal thickness in affected eyes [Fig. 3c].
OCTA measurements of the choriocapillaris flow in chronic CSCR has demonstrated regions of hypoperfusion surrounded by a hyperperfused area [Fig. 3b] that have a moderate correspondence with late staining on ICGA. A similar study by Xu et al. has confirmed these OCTA findings and demonstrated their disappearance as soon as 3 months after half-dose photodynamic therapy (PDT). The hyperperfusion demonstrated on OCTA of the choriocapillaris in chronic CSCR may be reactive and may cause an increased hydrostatic pressure within the fenestrated vessels of the choriocapillaris.
Choroidal Biomarkers in Polypoidal Choroidal Vasculopaty/Aneurysmal Type 1
ICGA has been the gold standard imaging modality to diagnose PCV/AT1. Characteristic ICGA features include branching vascular network and aneurysms [Fig. 4a-c]. In addition, markedly dilated and hyperpermeable choroidal vessels have been observed in the mid- and late-phases of ICGA in eye with PCV. These abnormally dilated large choroidal vessels typically appear as a cluster of relatively straight and dilated vessels. Compared with normal choroidal vessels, these “pachyvessels” do not taper toward the posterior pole but retain their large caliber and terminate abruptly. By studying cross-sectional OCT with ICGA [Fig. 4d], these vessels have increased diameter and appear as large hyporeflective lumen on OCT and can be seen to arise predominantly from Haller's layer.
More recently, studies based on SD-OCT further suggest that the abnormally dilated choroidal vessels (pachyvessels) may result in compression and ischemia of the overlying choriocapillaris and may contribute to the pathogenesis of PCV. Ischemia of the choriocapillaris is believed to result in increased extravasation of fluid from the choriocapillaris or larger choroidal vessels, leading to the observation of choroidal hyperpermeability. Choroidal hyperpermeability is characterized by multifocal areas of hyperfluorescence with blurred margins which are best observed in late phase (10–15 minutes) ICGA. Other features commonly observed on ICGA in eyes with PCV/AT1 include choroidal venous dilatation, choroidal filling defects, delayed arterial filling in the early phase, and focal or punctate hyperfluorescence. Both diffuse and punctate hyperfluorescence on ICGA have been frequently observed also in the contralateral eyes of patients with PCV/AT1.
Although eyes with choroidal hyperpermeability often have increased choroidal thickness, not all eyes with thick choroids exhibit choroidal hyperpermeability. Recent imaging studies combining ICGA and SD-OCT findings have suggested that choroidal vascular hyperpermeability may be followed by choriocapillaris atrophy and subsequent clinical manifestation in the form of retinal pigment epitheliopathy and PED. It has been further hypothesized that the choriocapillaris attenuation may produce an ischemic microenvironment which promotes VEGF expression and development of type 1 neovascularization. Development of aneurysms in chronic type 1 NV eventually leads to the clinical manifestation of PCV/AT1.
As well as having a potential role in the pathogenesis of PCV/AT1, choroidal hyperpermeability may also have a prognostic role. Choroidal hyperpermeability has been reported in 10%–50% of eyes with PCV. Several studies have reported poorer response and persistent fluid after anti-VEGF therapy in eyes with choroidal hyperpermeability. In a recent study, choroidal hyperpermeability, but not choroidal thickness, was associated with better visual outcome in eyes with PCV treated with combination therapy (PDT combined with anti-VEGF). Furthermore, eyes with CVH required lower injection number in combination therapy. The authors suggested that PDT may benefit eyes with choroidal hyperpermeability by modulating or occluding the abnormal hyperpermeable choroidal vessels and lead to reduction in the hydrostatic pressure of the choroid. Therefore, choroidal hyperpermeability may be a potential prognostic biomarker for selecting patients for combination therapy.
The constellation of morphological changes commonly seen in eyes with PCV/AT1, including increased choroidal thickness (on OCT) and hyperpermeability (on ICGA), attenuation of choriocapillaris, and presence of pachyvessels is also seen in many eyes with CSCR, PPE, PNV, focal choroidal excavation, and peripapillary pachychoroid syndrome. Together, these clinical entities are now recognized as clinical manifestations within the pachychoroid spectrum. Central to the concept of “pachychoroid disease” is that the choroidal alterations have key functional implications which have pathogenic importance. The fact that these different manifestations share a common underlying pathogenic process further help explain the overlapping features observed, as well as progression from one form to another. For example, neovascularization with or without aneurysmal changes may arise from eyes with a background of chronic CSC. These patients tended to be younger and have absent or minimal soft drusen compared with patients with neovascular AMD. It has been postulated that this type of neovascularization may have a different etiology compared with neovascular AMD.
Despite the compelling imaging findings that demonstrate alterations within the choroid in PCV/AT1, there remain areas which need further clarification. The mechanisms which lead to the characteristic choroidal changes described remain to be elucidated. Congestion of choroidal blood flow and increased hydrostatic pressure have been proposed as possible mechanisms. To answer this question, future imaging studies that enable in vivo determination of direction and velocity of blood flow within the choroid will be needed. Novel therapies targeting at “decongesting” the choroid and prevention of choriocapillaris may offer new therapeutic approaches to treating PCV/AT1.
Choroidal Biomarkers in Myopic Eyes
Progressive atrophy of the RPE has been observed in myopic eyes and can be clinically detected as increasing severity of myopic macular degeneration. The International meta-analysis for pathologic myopia (META-PM) classification system categorizes MMD with increasing severity into category 1 (no change), category 2 (tessellated fundus), category 3 (diffuse atrophy), category 4 (patchy atrophy), and category 5(macular atrophy). The risk of visual loss as well as complications such as myopic choroidal neovascularization increases with increasing MMD severity. However, the underlying mechanism that leads to progression in MMD remains poorly understood.
Pronounced choriocapillary obstruction in a lobular fashion has been observed in histological examination of highly myopic eyes. In these areas, choriocapillaris loss is seen, leaving behind choroidal arterioles. Using OCT, decreased choroidal thickness has been observed non-invasively in myopic eyes in vivo. The significance of choroidal thinning or atrophy in the development of MMD has been studied by several groups. For example, reduction in choroidal thickness was found to be more strongly associated with severity of myopic macular degeneration than scleral thickness, suggesting that progressive loss of choroidal vasculature may have a significant pathogenic role in the development of MMD.
However, studying the choriocapillaris using traditional modalities such as fluorescein or ICGA has yielded limited information, due to the lack of depth resolution and leakage of dye within the choriocapillaris. With the advent of OCTA, the choriocapillaris may be assessed in a depth-resolved manner. This can be achieved by direct visualization using a slab 0–10 μm deep to the RPE–Bruch's membrane complex. However, projection artifacts from overlying retinal vasculature often interfere with interpretation. Hence, a second, “indirect” method has been proposed, in which the interrogation slab is placed 34–44 μm deep to the RPE–Bruch's membrane complex. Using this method, the choriocapillaris network can be seen as a sheet of hyperreflectivity interspersed with circular areas with low or no signal, which represent the lobular pattern of the choriocapillaris meshwork. This method has the advantage of reducing projection artifacts from retinal vasculature. The deeper choroidal vessels appear hyporeflective in the presence of intact RPE and choriocapillaris network but become hyperreflective if there is loss of the overlying RPE and choriocapillaris.
OCTA changes in eyes with lacquer cracks were evaluated in one study. Choriocapillaris defects observed on OCTA were shorter than the full extent of the lacquer crack measured using ICGA. These findings suggest that the choriocapillaris impairment in lacquer cracks is likely secondary to Bruch's membrane and RPE changes.
In contrast, choriocapillaris flow impairment may precede the development of significant RPE changes. In eyes with patchy atrophy, it is not surprising to find that complete loss of choriocapillaris can be seen. In eyes with diffuse atrophy, low flow density within the choriocapillaris was observed in 78%–81%. In highly myopic eyes with even milder fundus changes, such as tessellated fundus without clinically evident RPE atrophy, low-density choriocapillaris can be observed in up to 18%. The pattern of choriocapillaris flow impairment changed from predominantly localized to extensive with increasing severity of MMD. This observation suggests that disturbance in choriocapillaris flow may occur early in the pathogenesis of MMD development and progression. To further investigate this, longitudinal studies will be necessary to evaluate whether eyes with CC flow impairment are likely to develop severe MMD in future.
Several groups have attempted to quantify choriocapillaris flow. However, the repeatability and reproducibility of these parameters have not been demonstrated and normative values have not been established. Other specific challenges related to OCTA in highly myopic eyes include difficulty in accurate segmentation due to irregular choroid–scleral interface and extreme thinning of the choroid, as well as aberrant increase in signal transmission which may result from RPE loss. In addition, it is important to be mindful that lack of flow signal may not necessarily mean absence of flow, but merely that flow is below the detectable threshold. Conversely, eyes with detectable flow signals on OCTA may also still have decreased flow speed.
If choriocapillaris flow impairment is indeed an integral part of the pathogenesis and progression of MMD, strategies to protect the choriocapillaris before the development of permanent loss may provide a way to prevent or slow down MMD progression. Long-term longitudinal studies will be required to further investigate this hypothesis. Before that, further refinements in OCTA technology to improve segmentation accuracy, reduce artifacts, and quantify choriocapillaris flow will be needed. Finally, longitudinal studies will further clarify whether choriocapillaris loss may be a biomarker for individuals at risk of MMD progression.
Choroidal Biomarkers in Uveitic Entities
Acute posterior multifocal placoid pigment epitheliopathy
APMPPE is a rare disorder of uncertain etiology characterized by acute onset of multiple yellowish-white placoid lesions at the level of the RPE mainly affecting the posterior pole and rarely extending beyond suggested to be the most likely pathological event resulting in development of the characteristic placoid lesions.
In the acute stage, ICGA reveals hypocyanescence in areas of yellowish white placoid lesions in the early phase, which persists in the late phase of the angiogram indicating choroidal capillary non-perfusion. As the remission of placoid lesions progresses, the areas of hypocyanescence gradually become less hypocyanescent in the late phase and ultimately isocyanescent in the inactive stage of the disease. ICGA is able to detect several additional hypocyanescent lesions compared with those detected on FA, autofluorescence, and OCT. It also picks up choroidal perfusion defects much after the clinical and OCT resolution of the lesions.
In the acute stage, EDI-OCT reveals focal areas of choriocapillaris thickening and hyporeflectivity beneath the placoid lesions and an overall increase in the subfoveal choroidal thickness. In the inactive stage, along with resolution of outer retinal hyperreflectivity, EDI-OCT shows regression of focal areas of choriocapillaris thickening and hyporeflectivity along with a reduction in the full choroidal thickness. These changes precede the recovery of choriocapillaris hypoperfusion on ICGA.
In the acute stage, OCTA images at the level of the choriocapillaris show areas of hypoperfusion corresponding to areas of outer retinal hyperreflectivity and choriocapillaris thickening on EDI-OCT. OCTA choroidal flow attenuation has been shown to extend beyond the visible retinal involvement in some studies. It is important to differentiate between signal attenuation artifacts and true flow deficits on OCTA. There is recovery of choroidal flow, with appearance of distinct small-sized vascular channels with healing of the APMPPE lesions.
Serpiginous choroiditis and serpiginous-like choroiditis
Serpiginous choroiditis (SC) is a descriptive term for a progressive, recurrent, usually bilateral posterior uveitis characterized by a geographic pattern of choroiditis that typically extends centrifugally from the peripapillary area with an active advancing edge and affects the overlying RPE and the outer retina. Serpiginous-like choroiditis (SLC) is a distinct form of the disease, which has been particularly described in tuberculosis endemic countries to differentiate it from classic autoimmune SC. This entity is characterized by choroidal lesions that grow in a serpentine manner with an active advancing edge and healing center. Various clinical, imaging, and histopathological studies have shown that eyes with both SC and SLC have choriocapillaris hypoperfusion due to inflammation involving the inner choroidal layers (choriocapillaris).
ICGA shows multiple areas of hypocyanescence in the early phase (for both active and healed lesions) with fuzzy margins (active lesions). In the active stage, the lesions continue to appear hypocyanescent with ill-defined fuzzy edges in the late phase. However, in the healing stages, the borders of these hypocyanescent lesions become more discrete and well defined in the early phase of ICGA, whereas the late phase ICGA shows hypofluorescence with the islands of preserved choriocapillaris and medium-sized underlying choroidal vessels appearing as ill-defined late central isofluorescence [Fig. 5]. The hypofluorescent areas seen in the active stage represent choriocapillaris nonperfusion and correlate well with the areas of choriocapillaris thickening and hyporeflectance on EDI-OCT and areas of flow deficit on en face OCTA scans.
In the active stage of the disease, the EDI-OCT findings include decrease in choroidal reflectance and choriocapillaris hypoperfusion seen as increased choriocapillaris thickness and hyporeflectance in the area of the lesion. In the healing stages, EDI-OCT shows increased choroidal reflectance, choroidal thinning, and focal areas of choriocapillaris thinning and atrophy.
In the active stage of disease, segmentation just beneath the RPE–Bruch's membrane complex shows well-demarcated “dark areas” corresponding to the choroiditis lesions. These “dark areas” represent either capillary loss/hypoperfusion or sluggish flow that may be below the limits of detection. Some of these areas may result from decreased signal transmission (due to overlying outer retinal deposits or RPE hyperplasia) rather than true loss of blood flow. Therefore, it is imperative to analyze the en face OCTA images along with the structural en face and cross-sectional B scan images for proper interpretation of the areas of apparent flow deficit. The hypocyanescent areas on ICGA, which represent choriocapillaris hypoperfusion or atrophy, correlate well with the areas of flow deficit on enface OCTA maps. Moreover, OCTA enables better distinction between choriocapillaris atrophy and choriocapillaris hypoperfusion – both of which appear hypocyanescent on ICGA [Fig. 6]. This is due to demonstration of islands of preserved choriocapillaris and underlying medium to large choroidal vessels on OCTA in the healed stage which appear as mainly hypocyanescence with ill-defined late central isocyanescence on ICGA.
OCTA is also an immensely valuable tool in early detection of Type 1 and Type 2 choroidal neovascularization in patients of SLC which may otherwise be difficult to detect due to the masking effect of adjacent active and healed choroiditis lesions and pigmentary changes.
Vogt–Koyanagi–Harada (VKH) is defined as a bilateral, chronic granulomatous panuveitis, which may or may not be associated with central nervous system, auditory, and integumentary manifestations. It has been classified according to the revised diagnostic criteria. Exudative retinal detachment was found to be the most common and specific clinical feature diagnostic for acute VKH disease.
The inflammation primarily involves the choroidal stroma with subsequent involvement of the RPE and outer retina. ICGA has been shown to be very sensitive, not only in revealing the presence of small choroidal inflammatory foci but also in providing information on the choriocapillaris circulation and on inflammation of the choroidal stromal vessels.
Fig. 7 illustrates the changes on ICGA and other imaging modalities in a young male patient diagnosed with VKH disease.
- Early choroidal stromal vessel hyperfluorescence along with disturbance/delay in early choriocapillaris circulation
- Hypocyanescent dark dots that represent choroidal stromal inflammatory foci or granulomas. They can be further subclassified into two types:
This is the most useful sign for diagnosing subclinical disease activity and for monitoring the effect of therapy and is the last angiographic sign to resolve.
- Dark dots that become isofluorescent in the late phase indicate partial thickness inflammatory granulomas
- Dark dots that persist in the late phase indicate full thickness choroidal granulomas with overlying choriocapillaris nonperfusion.
- Fuzzy vascular patterns of large choroidal stromal vessels is seen in the intermediate phase that progresses to diffuse stromal hyperfluorescence in the late phase.
EDI-OCT and SS-OCT show markedly increased choroidal thickness in acute VKH disease and are able to quantify the changes in the subfoveal choroidal thickness following steroidal treatment. It has been shown that SS-OCT provides much better resolution images of the choroid than EDI-OCT, resulting in more measurable images especially in the acute stage of the disease when the choroid is severely swollen [Fig. 7]. Where both SS-OCT and EDI-OCT images are measurable, the measurements are comparable. In addition, choroidal granulomas in VKH may be visualized on EDI-OCT as hypo-reflective, homogeneous, and round lesions with well-defined margins with increased choroidal transmission effect visible beneath the granulomas.
The OCTA images at the level of the choriocapillaris layer show multiple dark foci of variable shapes and sizes with clearly demarcated edges that represent choriocapillaris hypoperfusion. It is important to rule out loss of signal transmission on structural en face and cross-sectional B scan images while interpreting the dark areas as flow deficit [Fig. 7].
On comparison with ICGA, the areas of flow deficit on OCTA show consistent correlation with the hypocyanescent spots indicating true choriocapillaris ischemia. Even in the clinical absence of choroiditis lesions or exudative retinal detachment, OCTA helps in picking up foci of choriocapillaris hypoperfusion/flow deficit, which correlates well with the hypocyanescent spots on ICGA thereby helping in the detection of subclinical active disease and instituting appropriate therapy. The dark foci on OCTA correspond to thickening and hyporeflectivity of the choriocapillaris layer on EDI-OCT. The resolution of flow deficit areas on OCTA correlates well with overall decrease in the subfoveal choroidal thickness and normalization of choriocapillaris thickness and pattern on EDI-OCT. Thus, OCTA is an effective adjunct that may be sensitive in monitoring disease activity in VKH and is a useful non-invasive too in the diagnosis and management of this condition.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
1. Hogan MJ, Alvarado JA, Wedell JE Histology of the Human Eye. 1971 Philadelphia W.B. Saunders
2. De Stefano ME, Mugnaini E. Fine structure of the choroidal coat of the avian eye. Vascularization, supporting tissue and innervation Anat Embryol (Berl). 1997;195:393–418
3. Olver JM. Functional anatomy of the choroidal circulation: Methyl methacrylate casting of human choroid Eye (Lond). 1990;4(Pt 2):262–72
4. Spraul CW, Lang GE, Lang GK, Grossniklaus HE. Morphometric changes of the choriocapillaris and the choroidal vasculature in eyes with advanced glaucomatous changes Vision Res. 2002;42:923–32
5. Krebs W, Krebs IP. Ultrastructural evidence for lymphatic capillaries in the primate choroid Arch Ophthalmol. 1988;106:1615–6
6. Do DV, Gower EW, Cassard SD, Boyer D, Bressler NM, Bressler SB, et al Detection of new-onset choroidal neovascularization using optical coherence tomography: The AMD DOC study Ophthalmology. 2012;119:771–8
7. Kotsolis AI, Killian FA, Ladas ID, Yannuzzi LA. Fluorescein angiography and optical coherence tomography concordance for choroidal neovascularisation in multifocal choroidtis Br J Ophthalmol. 2010;94:1506–8
8. Schneider U, Kuck H, Inhoffen W, Kreissig I. Indocyanine green angiographically well-defined choroidal neovascularization: Angiographic patterns obtained using the scanning laser ophthalmoscope Ger J Ophthalmol. 1995;4:67–74
9. Trabucchi G, Brancato R, De Molfetta V, Verdi M, Pece A, Introini U, et al Indocyanine green and fluorescein angiography of surgically excised macular choroidal neovascularizations: Correlations with histopathologic and ultrastructural findings Graefes Arch Clin Exp Ophthalmol. 1996;234:294–9
10. Nakajima M, Shimada H, Sato M, Yuzawa M. Comparison between indocyanine green angiography and histopathological observations of choroidal neovascular membrane in age-related macular degeneration Nippon Ganka Gakkai Zasshi. 1997;101:584–92
11. Reichel E, Duker JS, Puliafito CA. Indocyanine green angiography and choroidal neovascularization obscured by hemorrhage Ophthalmology. 1995;102:1871–6
12. Rush RB, Rush SW, Aragon AV 2nd, Ysasaga JE. Evaluation of choroidal neovascularization with indocyanine green angiography in neovascular age-related macular degeneration subjects undergoing intravitreal bevacizumab therapy Am J Ophthalmol. 2014;158:337–44
13. Eandi CM, Ciardella A, Parravano M, Missiroli F, Alovisi C, Veronese C, et al Indocyanine green angiography and optical coherence tomography angiography of choroidal neovascularization in age-related macular degeneration Invest Ophthalmol Vis Sci. 2017;58:3690–6
14. Roisman L, Zhang Q, Wang RK, Gregori G, Zhang A, Chen CL, et al Optical coherence tomography angiography of asymptomatic neovascularization in intermediate age-related macular degeneration Ophthalmology. 2016;123:1309–19
15. Invernizzi A, Agarwal A, Di Nicola M, Franzetti F, Staurenghi G, Viola F, et al Choroidal neovascular membranes secondary to intraocular tuberculosis misdiagnosed as neovascular age-related macular degeneration Eur J Ophthalmol. 2018;28:216–24
16. Pang CE, Freund KB. Pachychoroid neovasculopathy Retina. 2015;35:1–9
17. Warrow DJ, Hoang QV, Freund KB. Pachychoroid pigment epitheliopathy Retina. 2013;33:1659–72
18. Phasukkijwatana N, Freund KB, Dolz-Marco R, Al-Sheikh M, Keane PA, Egan CA, et al Peripapillary pachychoroid syndrome Retina. 2017
19. Chung H, Byeon SH, Freund KB. Focal choroidal excavation and its association with pachychoroid spectrum disorders: A review of the literature and multimodal imaging findings Retina. 2017;37:199–221
20. Dansingani KK, Balaratnasingam C, Naysan J, Freund KB. En face imaging of pachychoroid spectrum disorders with swept-source optical coherence tomography
21. Gal-Or O, Dansingani KK, Sebrow D, Dolz-Marco R, Freund KB. Inner choroidal flow signal attenuation in pachychoroid disease: Optical coherence tomography angiography Retina. 2018
22. Pichi F, Carrai P, Ciardella A, Behar-Cohen F, Nucci PCentral Serous Chorioretinopathy Study Group. . Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy Int Ophthalmol. 2016
23. Nicholson B, Noble J, Forooghian F, Meyerle C. Central serous chorioretinopathy: Update on pathophysiology and treatment Surv Ophthalmol. 2013;58:103–26
24. Chhablani J, Pichi F, Silva R, Casella AM, Murthy H, Banker A, et al Antiangiogenics in choroidal neovascularization associated with laser in central serous chorioretinopathy Retina. 2016;36:901–8
25. Spaide RF, Hall L, Haas A, Campeas L, Yannuzzi LA, Fisher YL, et al Indocyanine green videoangiography of older patients with central serous chorioretinopathy Retina. 1996;16:203–13
26. Kuroda S, Ikuno Y, Yasuno Y, Nakai K, Usui S, Sawa M, et al Choroidal thickness in central serous chorioretinopathy Retina. 2013;33:302–8
27. Jirarattanasopa P, Ooto S, Tsujikawa A, Yamashiro K, Hangai M, Hirata M, et al Assessment of macular choroidal thickness by optical coherence tomography and angiographic changes in central serous chorioretinopathy Ophthalmology. 2012;119:1666–78
28. Teussink MM, Breukink MB, van Grinsven MJ, Hoyng CB, Klevering BJ, Boon CJ, et al OCT angiography compared to fluorescein and indocyanine green angiography in chronic central serous chorioretinopathy Invest Ophthalmol Vis Sci. 2015;56:5229–37
29. Xu Y, Su Y, Li L, Qi H, Zheng H, Chen C, et al Effect of photodynamic therapy on optical coherence tomography angiography in eyes with chronic central serous chorioretinopathy Ophthalmologica. 2017;237:167–72
30. Cheung CM, Lai TY, Ruamviboonsuk P, Chen SJ, Chen Y, Freund KB, et al Polypoidal choroidal vasculopathy: Definition, pathogenesis, diagnosis, and management Ophthalmology. 2018;125:708–24
31. Ersoz MG, Arf S, Hocaoglu M, Sayman Muslubas I, Karacorlu M. Indocyanine green angiography of pachychoroid pigment epitheliopathy Retina. 2017
32. Prünte C, Flammer J. Choroidal capillary and venous congestion in central serous chorioretinopathy Am J Ophthalmol. 1996;121:26–34
33. Kitaya N, Nagaoka T, Hikichi T, Sugawara R, Fukui K, Ishiko S, et al Features of abnormal choroidal circulation in central serous chorioretinopathy Br J Ophthalmol. 2003;87:709–12
34. Iida T, Kishi S, Hagimura N, Shimizu K. Persistent and bilateral choroidal vascular abnormalities in central serous chorioretinopathy Retina. 1999;19:508–12
35. Ferrara D, Mohler KJ, Waheed N, Adhi M, Liu JJ, Grulkowski I, et al En face enhanced-depth swept-source optical coherence tomography
features of chronic central serous chorioretinopathy Ophthalmology. 2014;121:719–26
36. Yang L, Jonas JB, Wei W. Choroidal vessel diameter in central serous chorioretinopathy Acta Ophthalmol. 2013;91:e358–62
37. Yanagi Y, Ting DS, Ng WY, Lee SY, Mathur R, Chan CM, et al Choroidal vascular hyperpermeability as a predictor of treatment response for polypoidal choroidal vasculopathy Retina. 2017
38. Hata M, Oishi A, Shimozono M, Mandai M, Nishida A, Kurimoto Y, et al Early changes in foveal thickness in eyes with central serous chorioretinopathy Retina. 2013;33:296–301
39. Pang CE, Freund KB. Pachychoroid pigment epitheliopathy may masquerade as acute retinal pigment epitheliitis Invest Ophthalmol Vis Sci. 2014;55:5252
40. Dansingani KK, Balaratnasingam C, Klufas MA, Sarraf D, Freund KB. Optical coherence tomography angiography of shallow irregular pigment epithelial detachments in pachychoroid spectrum disease Am J Ophthalmol. 2015;160:1243–54.e2
41. Dansingani KK, Gal-Or O, Sadda SR, Yannuzzi LA, Freund KB. Understanding aneurysmal type 1 neovascularization (polypoidal choroidal vasculopathy): A lesson in the taxonomy of ‘expanded spectra‘ – A review Clin Exp Ophthalmol. 2018;46:189–200
42. Balaratnasingam C, Lee WK, Koizumi H, Dansingani K, Inoue M, Freund KB, et al Polypoidal choroidal vasculopathy: A distinct disease or manifestation of many? Retina. 2016;36:1–8
43. Koizumi H, Yamagishi T, Yamazaki T, Kinoshita S. Relationship between clinical characteristics of polypoidal choroidal vasculopathy and choroidal vascular hyperpermeability Am J Ophthalmol. 2013;155:305–13.e301
44. Cho HJ, Kim HS, Jang YS, Han JI, Lew YJ, Lee TG, et al Effects of choroidal vascular hyperpermeability on anti-vascular endothelial growth factor treatment for polypoidal choroidal vasculopathy Am J Ophthalmol. 2013;156:1192–2000
45. Nomura Y, Yanagi Y. Intravitreal aflibercept for ranibizumab-resistant exudative age-related macular degeneration with choroidal vascular hyperpermeability Jpn J Ophthalmol. 2015;59:261–5
46. Sonoda S, Sakamoto T, Otsuka H, Yoshinaga N, Yamashita T, Ki IY, et al Responsiveness of eyes with polypoidal choroidal vasculopathy with choroidal hyperpermeability to intravitreal ranibizumab BMC Ophthalmol. 2013;13:43
47. Cheung CMG, Lee WK, Koizumi H, Dansingani K, Lai TYY, Freund KB. Pachychoroid disease Eye (Lond). 2018 doi: 10.1038/s41433-018-0158-4. [Epub ahead of print]
48. Yannuzzi LA, Freund KB, Goldbaum M, Scassellati-Sforzolini B, Guyer DR, Spaide RF, et al Polypoidal choroidal vasculopathy masquerading as central serous chorioretinopathy Ophthalmology. 2000;107:767–77
49. Fung AT, Yannuzzi LA, Freund KB. Type 1 (sub-retinal pigment epithelial) neovascularization in central serous chorioretinopathy masquerading as neovascular age-related macular degeneration Retina. 2012;32:1829–37
50. Spaide RF, Campeas L, Haas A, Yannuzzi LA, Fisher YL, Guyer DR, et al Central serous chorioretinopathy in younger and older adults Ophthalmology. 1996;103:2070–9
51. Ohno-Matsui K, Lai TY, Lai CC, Cheung CM. Updates of pathologic myopia Prog Retin Eye Res. 2016;52:156–87
52. Ohno-Matsui K, Kawasaki R, Jonas JB, Cheung CM, Saw SM, Verhoeven VJ, et al International photographic classification and grading system for myopic maculopathy Am J Ophthalmol. 2015;159:877–83.e7
53. Okabe S, Matsuo N, Okamoto S, Kataoka H. Electron microscopic studies on retinochoroidal atrophy in the human eye Acta Med Okayama. 1982;36:11–21
54. Mrejen S, Spaide RF. Optical coherence tomography: Imaging of the choroid and beyond Surv Ophthalmol. 2013;58:387–429
55. Cheung CM, Loh BK, Li X, Mathur R, Wong E, Lee SY, et al Choroidal thickness and risk characteristics of eyes with myopic choroidal neovascularization Acta Ophthalmol. 2013;91:e580–1
56. Wong CW, Phua V, Lee SY, Wong TY, Cheung CM. Is choroidal or scleral thickness related to myopic macular degeneration? Invest Ophthalmol Vis Sci. 2017;58:907–13
57. Tan AC, Tan GS, Denniston AK, Keane PA, Ang M, Milea D, et al An overview of the clinical applications of optical coherence tomography angiography Eye (Lond). 2018;32:262–86
58. Spaide RF, Fujimoto JG, Waheed NK. Image artifacts in optical coherence tomography angiography Retina. 2015;35:2163–80
59. Sayanagi K, Ikuno Y, Uematsu S, Nishida K. Features of the choriocapillaris in myopic maculopathy identified by optical coherence tomography angiography Br J Ophthalmol. 2017;101:1524–9
60. Wong CW, Teo YCK, Tsai STA, Ting SWD, Yeo YSI, Wong WKD, et al Characterization of the choroidal vasculature in myopic maculopathy with optical coherence tomographic angiography Retina. 2018 doi:10.1097/Iae.0000000000002233. [Epub ahead of print]
61. Al-Sheikh M, Phasukkijwatana N, Dolz-Marco R, Rahimi M, Iafe NA, Freund KB, et al Quantitative OCT angiography of the retinal microvasculature and the choriocapillaris in myopic eyes Invest Ophthalmol Vis Sci. 2017;58:2063–9
62. Mo J, Duan A, Chan S, Wang X, Wei W. Vascular flow density in pathological myopia: An optical coherence tomography angiography study BMJ Open. 2017;7:e013571
63. Fiore T, Iaccheri B, Androudi S, Papadaki TG, Anzaar F, Brazitikos P, et al Acute posterior multifocal placoid pigment epitheliopathy: Outcome and visual prognosis Retina. 2009;29:994–1001
64. Howe LJ, Woon H, Graham EM, Fitzke F, Bhandari A, Marshall J, et al Choroidal hypoperfusion in acute posterior multifocal placoid pigment epitheliopathy. An indocyanine green angiography study Ophthalmology. 1995;102:790–8
65. Mangeon M, Zett C, Amaral C, Novais E, Muccioli C, Andrade G, et al Multimodal evaluation of patients with acute posterior multifocal placoid pigment epitheliopathy and serpiginous choroiditis Ocul Immunol Inflamm. 2017:1–7
66. Dolz-Marco R, Sarraf D, Giovinazzo V, Freund KB. Optical coherence tomography angiography shows inner choroidal ischemia in acute posterior multifocal placoid pigment epitheliopathy Retin Cases Brief Rep. 2017;11(Suppl 1):S136–43
67. Werner JU, Enders C, Lang GK, Lang GE. Multi-modal imaging including optical coherence tomography angiography in patients with posterior multifocal placoid pigment epitheliopathy Ophthalmic Surg Lasers Imaging Retina. 2017;48:727–33
68. Nazari Khanamiri H, Rao NA. Serpiginous choroiditis and infectious multifocal serpiginoid choroiditis Surv Ophthalmol. 2013;58:203–32
69. De Luigi G, Mantovani A, Papadia M, Herbort CP. Tuberculosis-related choriocapillaritis (multifocal-serpiginous choroiditis): Follow-up and precise monitoring of therapy by indocyanine green angiography Int Ophthalmol. 2012;32:55–60
70. Giovannini A, Ripa E, Scassellati-Sforzolini B, Ciardella A, Tom D, Yannuzzi L, et al Indocyanine green angiography in serpiginous choroidopathy Eur J Ophthalmol. 1996;6:299–306
71. Barondes MJ, Sponsel WE, Stevens TS, Plotnik RD. Tuberculous choroiditis diagnosed by chorioretinal endobiopsy Am J Ophthalmol. 1991;112:460–1
72. Khan HA, Shahzad MA. Multimodal imaging of serpiginous choroiditis Optom Vis Sci. 2017;94:265–9
73. Invernizzi A, Agarwal A, Cozzi M, Viola F, Nguyen QD, Staurenghi G, et al Enhanced depth imaging optical coherence tomography features in areas of choriocapillaris hypoperfusion Retina. 2016;36:2013–21
74. Mandadi SK, Agarwal A, Aggarwal K, Moharana B, Singh R, Sharma A, et al Novel findings on optical coherence tomography angiography in patients with tubercular serpiginous-like choroiditis Retina. 2017;37:1647–59
75. Aggarwal K, Agarwal A, Sharma A, Sharma K, Gupta VOCTA Study Group. . Detection of type 1 choroidal neovascular membranes using optical coherence tomography angiography in tubercular posterior uveitis Retina. 2018
76. Read RW, Holland GN, Rao NA, Tabbara KF, Ohno S, Arellanes-Garcia L, et al Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: Report of an international committee on nomenclature Am J Ophthalmol. 2001;131:647–52
77. Herbort CP, Mantovani A, Bouchenaki N. Indocyanine green angiography in Vogt-Koyanagi-Harada disease: Angiographic signs and utility in patient follow-up Int Ophthalmol. 2007;27:173–82
78. Maruko I, Iida T, Sugano Y, Oyamada H, Sekiryu T, Fujiwara T, et al Subfoveal choroidal thickness after treatment of Vogt-Koyanagi-Harada disease Retina. 2011;31:510–7
79. Nakayama M, Keino H, Okada AA, Watanabe T, Taki W, Inoue M, et al Enhanced depth imaging optical coherence tomography of the choroid in Vogt-Koyanagi-Harada disease Retina. 2012;32:2061–9
80. Hosoda Y, Uji A, Hangai M, Morooka S, Nishijima K, Yoshimura N, et al Relationship between retinal lesions and inward choroidal bulging in Vogt-Koyanagi-Harada disease Am J Ophthalmol. 2014;157:1056–63
81. Chee SP, Chan SN, Jap A. Comparison of enhanced depth imaging and swept source optical coherence tomography in assessment of choroidal thickness in Vogt-Koyanagi-Harada disease Ocul Immunol Inflamm. 2017;25:528–32
82. Aggarwal K, Agarwal A, Mahajan S, Invernizzi A, Mandadi SK, Singh R, et al The role of optical coherence tomography angiography in the diagnosis and management of acute Vogt-Koyanagi-Harada disease Ocul Immunol Inflamm. 2018;26:142–53